These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
198 related items for PubMed ID: 12866308
21. [Misleading about type 2 diabetes and insulin]. Meland E. Tidsskr Nor Laegeforen; 2005 Dec 15; 125(24):3519-20; author reply 3520. PubMed ID: 16357910 [No Abstract] [Full Text] [Related]
22. [Misleading about insulin administration to patients with diabetes]. Johansen OE, Birkeland KI. Tidsskr Nor Laegeforen; 2005 Aug 25; 125(16):2247; author reply 2247. PubMed ID: 16138161 [No Abstract] [Full Text] [Related]
23. Insuline glusine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther; 2006 Apr 24; 48(1233):33-4. PubMed ID: 16625142 [Abstract] [Full Text] [Related]
24. An update on the long-acting insulin analogue glargine. Thisted H, Johnsen SP, Rungby J. Basic Clin Pharmacol Toxicol; 2006 Jul 24; 99(1):1-11. PubMed ID: 16867163 [Abstract] [Full Text] [Related]
25. Insulin detemir: a new basal insulin analogue. Soran H, Younis N. Diabetes Obes Metab; 2006 Jan 24; 8(1):26-30. PubMed ID: 16367879 [Abstract] [Full Text] [Related]
26. [A new long-acting insulin analog. "Fewer hypoglycemias observed"]. Gallwitz B. MMW Fortschr Med; 2004 Jan 22; 146(3-4):47. PubMed ID: 15035450 [No Abstract] [Full Text] [Related]
27. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Pharmacotherapy; 2007 Jul 22; 27(7):948-62. PubMed ID: 17594200 [Abstract] [Full Text] [Related]
28. [Intensive insulin therapy]. Landgraf R, Huber RM, Bachmann A, Lohr R. Dtsch Med Wochenschr; 2008 Apr 22; 133(17):901-12. PubMed ID: 18415916 [No Abstract] [Full Text] [Related]
29. Clinical perspectives in type 2 diabetes care: optimizing glycemic control with insulin therapy. Diabetes Educ; 2005 Apr 22; Suppl():1-14; quiz 15-6. PubMed ID: 15786628 [No Abstract] [Full Text] [Related]
30. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Noh RM, Graveling AJ, Frier BM. Expert Opin Pharmacother; 2011 Oct 22; 12(14):2161-75. PubMed ID: 21668402 [Abstract] [Full Text] [Related]
31. [Intensive insulin therapy to prevent the progression of chronic vascular complications in type 2 diabetes mellitus]. Kishikawa H, Araki E, Wake N, Shichiri M. Nihon Rinsho; 2002 Sep 22; 60 Suppl 9():140-5. PubMed ID: 12386985 [No Abstract] [Full Text] [Related]
32. Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody--a case report. Itoh A, Saisho Y, Mitsuishi M, Oikawa Y, Kawai T, Tanaka M, Shimada A, Itoh H. Diabetes Res Clin Pract; 2011 Nov 22; 94(2):e53-4; discussion e55. PubMed ID: 21724289 [No Abstract] [Full Text] [Related]
33. [Trust is good, control is better. Glucose tests, insulin syringes, needles]. Fink E. Pharm Unserer Zeit; 2001 Jan 22; 30(1):34-9. PubMed ID: 11233181 [No Abstract] [Full Text] [Related]
34. Diabetes mellitus management in general practice: where are we? Staff M. Aust Fam Physician; 1999 Aug 22; 28(8):775. PubMed ID: 10495524 [No Abstract] [Full Text] [Related]
35. Lantus reduces blood glucose levels, less hypoglycemia in treatment of type 2 diabetes. Walczak IM. Diabetes Technol Ther; 2002 Aug 22; 4(5):735-6. PubMed ID: 12458566 [No Abstract] [Full Text] [Related]
36. Type II diabetes: insulin versus oral agents. Martin DB. N Engl J Med; 1986 May 15; 314(20):1314-5. PubMed ID: 3517646 [No Abstract] [Full Text] [Related]